Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DYNASTY-Breast02: DB-1303 versus physician's choice chemotherapy in HR-positive, HER2-low metastatic breast cancer
MOH_2024-05-05_013395Phase 3Active, not recruiting
- Sponsor
- Duality Biotherapeutics
- Start
- Mar 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of trastuzumab pamirtecan in breast cancer (2 arms), sponsored by Duality Biotherapeutics. Primary endpoint: Progression-free survival. Started Mar 2024; status: active, not recruiting.
02
Drugs
trastuzumab pamirtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2024-05-05_013395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-05-05_013395.